Summary
McKesson Corporation (MCK) has announced a significant restructuring of its reportable business segments, effective in the second quarter of fiscal year 2026. The company will now report financial results across four primary segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This change reflects the company's strategic allocation of resources and performance assessment by its Chief Operating Decision Maker. Notably, the Medical-Surgical Solutions segment is slated for separation into an independent company, as previously announced in May 2025. In addition to segment realignments, McKesson is progressing with the sale of its Norwegian operations, having entered into a definitive agreement. The company has also filed supplemental historical financial information, restated under the new segment structure, to provide investors with a clearer view of historical performance across these redefined segments. These changes, while impacting reporting, do not retroactively alter previously issued consolidated financial statements or historical earnings per diluted share.
Key Highlights
- 1McKesson is reorganizing its reporting structure into four key segments effective Q2 FY2026: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
- 2The Medical-Surgical Solutions segment is still intended for separation into an independent company, as announced in May 2025.
- 3McKesson has entered into a definitive agreement to sell its Norwegian operations.
- 4Supplemental historical financial data, presented under the new segment structure, is being filed for investor clarity.
- 5These segment changes are driven by the Chief Executive Officer's (Chief Operating Decision Maker's) approach to resource allocation and performance evaluation.
- 6The reporting changes do not impact previously issued consolidated financial statements or historical earnings per diluted share.